A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
Status:
RECRUITING
Trial end date:
2025-07-24
Target enrollment:
Participant gender:
Summary
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.